VolitionRx Partners with Sysmex to Optimize NETs Assay for Diagnostic Platform

Event summary

  • VolitionRx collaborates with Sysmex to optimize its Nu.Q® NETs H3.1 assay for Sysmex's diagnostic platform.
  • Gael Forterre, VolitionRx's Chief Commercial Officer, highlights the strategic alignment with Sysmex's expertise in hemostasis and thrombosis diagnostics.
  • The Nu.Q® NETs assay targets diseases associated with NETosis, including sepsis, with a Total Addressable Market of $3.8 billion.
  • Optimization phase begins following successful transfer of the assay onto Sysmex's platform.

The big picture

This collaboration aligns with VolitionRx's strategy to out-license its proprietary assays to established diagnostic companies, leveraging their regulatory expertise and installed base. Sysmex's leadership in hemostasis and thrombosis diagnostics positions the partnership to address a significant unmet need in diseases associated with NETosis, potentially expanding VolitionRx's market presence in acute and chronic disease monitoring.

What we're watching

Market Penetration
How VolitionRx's ability to leverage Sysmex's global reach will impact the adoption of the Nu.Q® NETs assay.
Regulatory Approval
Whether the collaboration will accelerate regulatory clearance for the Nu.Q® NETs assay in key markets.
Commercialization Pace
The pace at which VolitionRx can transition from optimization to full commercialization of the assay.

Related topics

Biotechnology